dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gómez‑Caamaño, A. |
dc.contributor.author | González‑San Segundo, C. |
dc.contributor.author | Henríquez, I. |
dc.contributor.author | Maldonado Pijoan, Javier |
dc.contributor.author | Zapatero, A. |
dc.date.accessioned | 2021-04-15T07:38:14Z |
dc.date.available | 2021-04-15T07:38:14Z |
dc.date.issued | 2019-04 |
dc.identifier.citation | Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A, Cabeza Rodríguez MA, et al. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. Clin Transl Oncol. 2019 Apr;21(4):420–32. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/5858 |
dc.description | Castration-resistant prostate cancer; Radiation oncology; Consensus |
dc.description.abstract | Background: The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required.
Methods: A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group.
Results: A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring.
Conclusions: The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;21(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Tractament |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | /therapy |
dc.subject.mesh | Clinical Decision-Making |
dc.title | Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-018-1940-2 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | /terapia |
dc.subject.decs | toma de decisiones clínicas |
dc.relation.publishversion | https://link.springer.com/article/10.1007%2Fs12094-018-1940-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gómez-Caamaño A] Radiation Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain. [González-San Segundo C] Radiation Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Henríquez I] Radiation Oncology Department, Hospital Universitario Sant Joan de Reus, Tarragona, Spain. [Maldonado X] Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Zapatero A] Radiation Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain |
dc.identifier.pmid | 30293231 |
dc.identifier.wos | 000461394500004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |